Modified host cells and uses thereof

Details Modified host cells and uses thereof Modified host cells and uses thereof

2009-07-21

2011-12-20

Bristol, Lynn (Department: 1643)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Animal cell, per se, expressing immunoglobulin, antibody, or...

C435S289100, C435S358000

Reexamination Certificate

active

08080415

ABSTRACT:
The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.

REFERENCES:
patent: 6602684 (2003-08-01), Umana et al.
patent: 6737056 (2004-05-01), Presta
patent: 6946292 (2005-09-01), Kanda et al.
patent: 7393683 (2008-07-01), Kanda et al.
patent: 7416727 (2008-08-01), Presta
patent: 7425446 (2008-09-01), Kanda et al.
patent: 2004/0072290 (2004-04-01), Umana et al.
patent: 2005/0074843 (2005-04-01), Umana et al.
patent: 2005/0079605 (2005-04-01), Umana et al.
patent: 2005/0272128 (2005-12-01), Umana et al.
patent: 2005/0272916 (2005-12-01), Hanai et al.
patent: 2006/0064781 (2006-03-01), Kanda et al.
patent: 2006/0182741 (2006-08-01), Bourel et al.
patent: 2007/0015239 (2007-01-01), Bihoreau et al.
patent: 2008/0118501 (2008-05-01), Schindler et al.
patent: 2008/0280322 (2008-11-01), Umana et al.
patent: 2009/0285830 (2009-11-01), Adams et al.
patent: 2010/0081150 (2010-04-01), Liu et al.
patent: 2010/0081172 (2010-04-01), Liu et al.
patent: 2010/0081794 (2010-04-01), Liu et al.
patent: 2011/0059075 (2011-03-01), Wittrup et al.
patent: 1176195 (2002-01-01), None
patent: 1331266 (2003-07-01), None
patent: 1176195 (2005-03-01), None
patent: 1914244 (2008-04-01), None
patent: 1914244 (2008-06-01), None
patent: 2008113663 (2008-05-01), None
patent: WO 2005/012358 (2005-02-01), None
patent: WO 2005/040221 (2005-05-01), None
patent: WO 2005/012358 (2005-09-01), None
patent: WO 2006/014679 (2006-02-01), None
patent: WO 2006/014685 (2006-02-01), None
patent: WO 2006/133148 (2006-12-01), None
patent: WO 2007/028144 (2007-03-01), None
patent: WO 2007/029054 (2007-03-01), None
patent: WO 2007/048077 (2007-04-01), None
patent: WO 2006/133148 (2007-05-01), None
patent: WO 2007/053767 (2007-05-01), None
patent: WO 2007/028144 (2007-06-01), None
patent: WO 2007/048077 (2007-07-01), None
patent: WO 2007/084672 (2007-07-01), None
patent: WO 2007/084672 (2007-10-01), None
patent: WO 2007/146847 (2007-12-01), None
patent: WO 2007/146847 (2008-11-01), None
“Culture medium” definition (dictionary.com; pp. 1-2, May 4, 2011).
“Fermentor” definition (drugs.com; p. 1, May 4, 2011).
Jones et al (Biochem. Biophys. Acta 1726(2): 121-137 (2005).
Wright et al (Springer Semin Immunopathology ,15 :259-273 (1993).
Delente (Trends in Biotechnology 3, letters to editor, No. 9, (1985)).
Olden et al (Biochem et Biophys Acta 650:209-232 (1982).
Perkel et al. (Proc. Soc. Exp. Biol. Med.1989 Mar.;190 (3):286-93; Abstract).
Banerjee, et al. The evolution of N-glycan-dependent endoplasmic reticulum quality control factors for glycoprotein folding and degradation. Proc Natl Acad Sci U S A. Jul. 10, 2007;104(28):11676-81.
Czlapinski, et al. Synthetic glycobiology: Exploits in the Golgi compartment. Curr Opin Chem Biol. Dec. 2006;10(6):645-51.
International search report dated Nov. 24, 2009 for PCT Application No. US2009/51325.
Lowe, et al. A genetic approach to Mammalian glycan function. Annu Rev Biochem. 2003;72:643-91.
Natsume, et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J Biochem. Sep. 2006;140(3):359-68.
Sallustio, et al. Novel genetic instability associated with a developmentally regulated glycosyltransferase locus in Chinese hamster ovary cells. Somat Cell Mol Genet. Sep. 1989;15(5):387-400.
Shields, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. Jul. 26, 2002;277(30):26733-40.
Shinkawa, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. Jan. 31, 2003;278(5):3466-73.
Yamane-Ohnuki, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. Sep. 5, 2004;87(5):614-22.

Affiliated with

Also associated with

Rating

Modified host cells and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified host cells and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified host cells and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313619